Extravasation of oxaliplatin (Eloxatin®) -: clinical course

被引:19
|
作者
Baur, M
Kienzer, HR
Rath, T
Dittrich, C
机构
[1] Kaiser Franz Josef Spital, Med Abt Onkol 3, Ludwig Boltzmann Inst Angew Krebsforsch, Vienna, Austria
[2] Univ Vienna, Chirurg Abt, Inst Plast & Rekonstrukt Chirurg, A-1010 Vienna, Austria
来源
ONKOLOGIE | 2000年 / 23卷 / 05期
关键词
oxaliplatin; extravasation; vesicant; tissue necrosis; local reaction;
D O I
10.1159/000027218
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Up to now the cytostatic oxaliplatin was classified as nonvesicant. This is the first report on tissue necrosis induced by oxaliplatin extravasation in literature. A clinical course following oxaliplatin extravasation is reported. Case Report: A 52-year-old white female with adenocarcinoma of the colon and hepatic and pulmonary metastases received palliative chemotherapy consisting of oxaliplatin, leucovorin, and 5-fluorouracil. By mistake oxaliplatin infusion extravasated subcutaneously in the left forearm; consequently, a painless red swelling occurred without any sign of further damage of the tissue. The infusion cannula was removed and oxaliplatin was infused into the right median cubital vein at the elbow. Again oxaliplatin extravasated subcutaneously. A severe painful necrotic reaction of the underlying flexor muscles of the right elbow developed, disabling the patient for 2 months, showing red-brown painful swelling, sclerosis of the skin, induration, fixation, and immobilization of the right elbow. Nonsteroidal analgesics and antibiotics were given, and lymphatic drainage and physiotherapy performed as generally accepted polypragmatic unspecific therapeutic procedure. After 2 months, the patient was able to bow and extend the right elbow except for an extension deficit of 20 degrees, pro- and supination became possible again, pain had completely resolved and strength recovered without limitation. Sclerosis of the skin and stiffness of the underlying tissue were slowly subsiding. Conclusion: Oxaliplatin can induce severe necrosis of underlying muscles by extravasation and therefore must be considered as a vesicant. Therefore oxaliplatin should be applied via a central venous access.
引用
收藏
页码:468 / 471
页数:4
相关论文
共 50 条
  • [21] 'Tomudex' (raltitrexed) plus oxaliplatin (Eloxatin) in previously untreated metastatic colorectal cancer (MCRC) patients:: An active combination
    Bennouna, J
    Seitz, JF
    Paillot, B
    Gamelin, E
    François, E
    Conroy, T
    Raoul, JL
    Becouarn, Y
    Cvitkovic, FB
    Nasca, S
    Ychou, M
    Smith, M
    Douillard, JY
    Fandi, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S75 - S75
  • [22] In vitro and in vivo effects of the combination of SR57746A (Xaliproden), a neuroprotective agent, with oxaliplatin (ELOXATIN®) in colon tumors
    Vrignaud, Patricia
    Granda, Teresa G.
    Bourrie, Bernard
    Casellas, Pierre
    Bissery, Marie-Christine
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [23] Surgical management after Oxaliplatin extravasation: A case report and literature review
    Van Praet, Laura
    Boecxstaens, Veerle
    Douchy, Thomas
    [J]. JOURNAL OF VASCULAR ACCESS, 2023, 24 (06): : 1239 - 1243
  • [24] Extrarenal extravasation observed in the course of intravenous urography
    Narath, PA
    [J]. JOURNAL OF UROLOGY, 1938, 39 (01): : 65 - 74
  • [25] TAXOL-INDUCED SOFT-TISSUE INJURY SECONDARY TO EXTRAVASATION - CHARACTERIZATION BY HISTOPATHOLOGY AND CLINICAL COURSE
    AJANI, JA
    DODD, LG
    DAUGHERTY, K
    WARKENTIN, D
    ILSON, DH
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (01) : 51 - 53
  • [26] Clinical course of patients with oxaliplatin-associated neuropathy: N08CB (Alliance).
    Pachman, Deirdre R.
    Qin, Rui
    Seisler, Drew K.
    Ellen, M.
    Smith, Lavoie
    Beutler, Andreas S.
    Ta, Lauren E.
    Lafky, Jacqueline M.
    Wagner-Johnston, Nina
    Ruddy, Kathryn Jean
    Dakhil, Shaker R.
    Grothey, Axel
    Loprinzi, Charles L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [27] Nanocomposite of reduced nanographene oxide with B-lactoglobulin protein (rNGO/B-Lg) as a carrier of the anticancer drug oxaliplatin (Eloxatin)
    Almajidi, Yasir Qasim
    Althomali, Raed H.
    Maashi, Marwah Suliman
    Ahmad, Irfan
    Saleh, Ebraheem Abdu Musad
    Kareem, A. K.
    Romero-Parra, Rosario Mireya
    Alawsi, Taif
    Salim, Khulood Saadoon
    [J]. DIAMOND AND RELATED MATERIALS, 2023, 136
  • [28] EVIDENCE AND COURSE OF THE SPONTANEOUS EXTRAVASATION OF CONTRAST REMEDIES IN THE EXCRETION UROGRAM
    LANGE, H
    GOTTHARDT, E
    HILLER, U
    OCHS, U
    [J]. ZEITSCHRIFT FUR UROLOGIE UND NEPHROLOGIE, 1987, 80 (01): : 43 - 46
  • [29] OVERDOSE OF OXALIPLATIN: A CLINICAL CASE
    Compostella, A.
    Carli, M.
    Bisogno, G.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : S4 - S5
  • [30] Oxaliplatin clinical activity: a review
    Misset, JL
    Bleiberg, H
    Sutherland, W
    Bekradda, M
    Cvitkovic, E
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 35 (02) : 75 - 93